Veru Redirects Sabizabulin to Daraxonrasib-Resistant Pancreatic Cancer After Encouraging Preclinical Results
VERU sits 38% above its 52-week low of $2.05 on light trading volume (0.4× avg).
Summary
Veru announced positive preclinical data for sabizabulin in daraxonrasib-resistant pancreatic cancer and will pivot development toward a Phase 2b trial in that indication, discontinuing the cardiovascular inflammation program.
Key Events · Product Development and Regulatory · VERU
-
Sabizabulin Shows Activity in Daraxonrasib-Resistant Cancer
New preclinical data show sabizabulin achieved an IC50 of 18.2nM in daraxonrasib-resistant pancreatic cancer cell lines, with collateral sensitivity (RI=0.25) versus a resistance index of 68 for daraxonrasib itself.
-
Pipeline Pivot to Pancreatic Cancer
Veru will advance sabizabulin into a planned Phase 2b clinical trial for metastatic KRAS-driven pancreatic cancer resistant to daraxonrasib, and will no longer pursue the cardiovascular inflammation indication.
-
Regulatory Path
The company plans to seek FDA regulatory clarity through a preIND meeting in calendar Q4 2026 before initiating the Phase 2b trial.
-
Enobosarm Program Remains on Track
The Phase 2b PLATEAU obesity trial is fully enrolled at 239 patients, with interim analysis expected in Q1 2027 and final topline data in Q4 2027.
Analysis · VERU · Life Sciences
A strategic pipeline reprioritization is underway at Veru. New preclinical data demonstrate that sabizabulin can overcome resistance to Revolution Medicines' daraxonrasib in KRAS-driven pancreatic cancer cell lines, with an IC50 of 18.2nM. The company will advance sabizabulin into a planned Phase 2b trial for this indication and discontinue its cardiovascular inflammation program. This shift is particularly meaningful given the company's going-concern warning and limited cash, as it concentrates resources on a high-unmet-need oncology opportunity while the enobosarm obesity program remains the near-term value driver.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 30% of the 1972 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VERU was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45M. The 52-week trading range was $2.05 to $7.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.